文献速递肺结节与肺癌

呼吸科医生对晚期非小细胞肺癌分子生物标志物检测的知识与实践模式调查

Knowledge and Practice Patterns Among Pulmonologists for Molecular Biomarker Testing in Advanced Non-small Cell Lung Cancer.
PubMed 文献 · Chest · 2021-06-26

该横断面研究对7238名呼吸科医生随机抽样进行电子问卷调查,共453名回复。结果显示介入培训、学术机构和机构政策与更高的生物标志物检测率相关,而社区实践和缺乏指导政策与较低检测率相关。呼吸科医生在晚期NSCLC评估、生物标志物知识及机构协调方面存在显著差异,可能导致检测不足。

要点

  • 介入培训、学术机构和机构政策与更高的生物标志物检测率相关。
  • 学术呼吸科医生比社区医生更常进行或转诊EBUS-TBNA(96% vs 83%)。
  • 呼吸科医生在晚期NSCLC评估和生物标志物知识上存在显著差异。

核心结论

  • 呼吸科医生在晚期NSCLC评估、生物标志物知识及机构协调方面存在显著差异,可能导致生物标志物检测未充分利用。
  • 介入培训比实践环境更能驱动生物标志物检测知识和实践的改善。

研究设计与样本

  • 横断面研究,对7238名呼吸科医生随机抽样进行电子问卷调查,共453名回复。

主要发现

  • 受访者肺癌患者量不同:51%每月评估1-4例新病例,19%每月评估>10例。
  • 介入培训、学术实践环境和较高EBUS-TBNA volume与对EBUS-TBNA推荐穿刺次数指南知识的增加相关(P < .05)。
  • 学术呼吸科医生比社区呼吸科医生更常进行或转诊EBUS-TBNA(96% vs 83%,P < .0005)。
  • 较高检测率与介入培训、学术环境和机构政策的存在相关,较低检测率与普通呼吸科医生、社区实践和缺乏指导性机构政策相关(P < .05)。

临床怎么用

  • 应加强介入培训以提升呼吸科医生对生物标志物检测的知识和实践。
  • 需要改善组织获取和跨学科协调,以确保符合条件患者接受全面检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Targeted therapies for advanced non-small cell lung cancer (NSCLC) with oncogenic drivers have caused a paradigm shift in care. Biomarker testing is needed to assess eligibility for these therapies. Pulmonologists often perform bronchoscopy, providing tissue for both pathologic diagnosis and biomarker analysis. We performed this survey to define the existing knowledge and practices regarding the pulmonologists' role in biomarker testing for advanced NSCLC. RESEARCH QUESTION: What is the current knowledge and practice of pulmonologists regarding biomarker testing and targeted therapies in advanced NSCLC? STUDY DESIGN AND METHODS: This cross-sectional study was performed using an electronic survey of a random sample of 7,238 pulmonologists. Questions focused on diagnostic steps and biomarker analyses for NSCLC. RESULTS: A total of 453 pulmonologists responded. Respondents vary by reported lung cancer patient volume, ranging from 51% evaluating one to four new cases per month to 19% evaluating > 10 cases per month. Interventional training, academic practice setting, and higher volume of endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) were associated with increased knowledge of practice guidelines for the number of recommended passes during EBUS-TBNA (P < .05). Academic pulmonologists more commonly performed or referred for EBUS-TBNA than community pulmonologists (96% and 83%, respectively; P < .0005). Higher testing rates were associated with interventional training, academic setting, and the presence of an institutional policy, whereas lower testing rates were associated with general pulmonologists, practice in community settings, and lack of a guiding institutional policy (P < .05). INTERPRETATION: Substantial differences among pulmonologists' evaluation of advanced NSCLC, variation in knowledge of available biomarkers and the importance of targeted therapies, and differences in institutional coordination likely lead to underutilization of biomarker testing. Interventional training appears to drive improved knowledge and practice for biomarker testing more than practice setting. Improvements are needed in tissue acquisition and interdisciplinary coordination to ensure universal and comprehensive testing for eligible patients.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Fox AH, Jett JR, Roy UB, et al. Knowledge and Practice Patterns Among Pulmonologists for Molecular Biomarker Testing in Advanced Non-small Cell Lung Cancer. Chest. 2021. PMID: 34181954. doi:10.1016/j.chest.2021.06.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。